Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen Premature

Sarepta Therapeutics (NASDAQ: SRPT ) today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission and confirmatory clinical study with eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Citing recent developments since Sarepta's last meeting